Read how a biotech VC firm sharpened investment strategy with data-driven insights, rare disease focus, and lifecycle support| Evaluate
Pharma shifts to predictable trends, focusing on major drugs for big diseases. Evaluate’s 2030 forecast explores obesity and new tech.| Evaluate
Pharma M&A and IPOs started strong in 2024 but saw significant drops in Q2, with fewer deals and only three companies going public.| Evaluate
Explore Evaluate's analysis of 200 top-selling drugs to uncover what makes billion-dollar blockbusters. Get the Billion Dollar Blueprint infographic now.| Evaluate
Discover how the loss of exclusivity for biologics by 2030 opens $120B in opportunities for biosimilars, shaping the industry's future.| Evaluate
Biopharma faces ongoing challenges in 2024, yet Q3 IPOs and venture funding show promise. M&A remains low. Dive into our latest analysis.| Evaluate
Pharmacological intervention can shift excess body weight, but questions remain. Explore market size, pipeline value, and key insights.| Evaluate
MASH UP? Are we witnessing the next multi-billion dollar breakthrough in liver health? Explore the possibilities in our latest eBook.| Evaluate
Explore how pharmaceutical companies add blockbuster drugs. Learn about internal development vs. acquisitions, strategic timing, top companies, and acquisition benefits.| Evaluate